https://www.selleckchem.com/pr....oducts/Odanacatib-(M
No-reflow is of prognostic value in ST-segment elevation myocardial infarction (STEMI) but has not been extensively investigated in young patients. Young patients with STEMI admitted within 12 hours from symptom onset and treated by primary percutaneous coronary intervention (pPCI) were recruited. Patients were classified into 2 groups based on postintervention thrombolysis in myocardial infarction (TIMI) flow grade; no-reflow TIMI flow grade 0, 1 or 2 (group 1; n = 27; 21 men, mean age 42 ± 4 years); and angiographic succes
Like
Comment
Share
